Odevixibat

H1 2026 results with sales growth of 23.5% at CER 1 , or 20.4% as reported, with the portfolio beyond Somatuline ® achieving sales growth of 24.8% 1 and core operating income of €845m, growing by 28.8% as reported, with a core operating margin of 38.6% of total sales, increasing by 2.5 points Upgraded FY 2026 financial guidance 2 : total sales growth greater than 20.0% at CER (prior guidance: greater than 13.0% at CER); core operating margin greater than 37.0% of total sales (prior guidance: greater than 35.0%) Delivering on strategy to accelerate the growth of key medicines and expand the pipeline, adding multiple anticipated near-term launches of assets with blockbuster potential across the three therapeutic areas. Driven by several positive Phase III readouts, for Dysport ® in episodic and chronic migraine, Iqirvo ® in primary biliary cholangitis and the acquisitions of Kartos Therapeutics 3 and Memo Therapeutics AG PARIS, FRANCE, 30 July 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2026. Extract of consolidated results H1 2026 H1 2025 % change €m €m Actual TCC Total Sales 2 190,2 1 819,8 20,4 % 23,5 % Core Operating Income 844,9 655,8 28,8 % Core operating margin 38,6 % 36,0 % +2,5 pts Core Consolidated Net Profit 607,7 508,3 19,6 % Core earnings per share (fully diluted) 7,33 € 6,07 € 20,7 % IFRS Operating Income 564,8 451,6 25,1 % IFRS operating margin 25,8 % 24,8 % +1,0 pts IFRS Consolidated Net Profit 402,6 335,5 20,0 % IFRS earnings per share (fully diluted) 4,86 € 4,00 € 21,4 % Free Cash Flow 651,7 483,2 34,9 % Closing net cash/(debt) 1 004,9 487,6 n/a “Our excellent first-half performance demonstrates the strength of Ipsen’s strategy, with all three therapeutic areas contributing to growth and the portfolio beyond Somatuline continuing to accelerate,” said David Loew, Chief Executive Officer, Ipsen. “This momentum enables us to upgrade our 2026 guidance while continuing to invest in innovation and future growth. Importantly, we have significantly strengthened our late-stage pipeline in the first half, with positive Phase III lifecycle management readouts for Dysport in episodic and chronic migraine and Iqirvo in primary biliary cholangitis, alongside the completed acquisition of Memo Therapeutics AG and the proposed acquisition of Kartos Therapeutics. These transactions add two innovative clinical assets—navtemadlin and potravitug—with the potential to address significant unmet needs and create long-term value. Our expanding pipeline and focused business development strategy further contribute to Ipsen’s sustainable growth outlook and our ability to bring meaningful innovation to patients worldwide.” Full-year 2026 guidance Based on the strong performance in the first half, Ipsen upgrades its financial guidance for 2026: ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Total sales growth greater than 20.0%, at constant currency. Based on the average level of exchange rates in June 2026, an adverse effect on total sales of around 1% of currencies is expected Core operating margin greater than 37.0% of total sales, which includes additional R&D expenses from anticipated early and mid-stage external innovation opportunities and assumes the dilutive impact of the acquisitions of Memo Therapeutics AG and Kartos Therapeutics Guidance 4 on total sales and core operating margin in 2026 is assuming accelerated sales growth of the portfolio excluding Somatuline and the continued growth of Somatuline sales despite potential entry of generic lanreotide. Pipeline progress since Q1 2026 Ipsen presented in May late-breaking Phase II data in Glabellar Lines for corabotase, its first-in-class recombinant neuroinhibitor (RNI™), demonstrating a rapid onset of action, a statistically superior peak effect versus placebo at Week 4 and a clinically significant sustained duration of effect, outperforming both placebo and Dysport at Week 24. Corabotase has been recognized by the WHO (World Health Organization) and USAN (United States Adopted Name) as a novel botase molecule. Ipsen announced positive topline Phase III results from the BEOND migraine program in July, with Dysport meeting the primary endpoint in both the episodic, E-BEOND and chronic, C-BEOND trials by demonstrating statistically significant reductions in monthly migraine days versus placebo. These results make Dysport the first botulinum toxin to show efficacy in Phase III trials across both episodic and chronic migraine prevention. Dysport was well tolerated, with a safety pro with its established use and no new safety signals identified. Ipsen intends to submit to regulatory authorities and detailed results will be presented at a future scientific congress. Ipsen announced positive topline results from the Phase IIIb ELSPIRE study of Iqirvo in primary biliary cholangitis (PBC) in July. The study met its primary endpoint, with 85% of patients receiving Iqirvo achieving alkaline phosphatase (ALP) normalization at Week 52 versus 23% on placebo (p=<0.0001), while maintaining a safety pro with previous studies and identifying no new safety signals. ELSPIRE evaluated patients with ALP levels of 1-1.67x ULN, and supports the potential to significantly expand the addressable population for Iqirvo. Ipsen plans to submit the data to regulatory authorities and present these data at an upcoming scientific congress. Ipsen announced in July that the Phase III BOLD trial evaluating Bylvay ® (odevixibat) versus placebo in patients with biliary atresia who had already undergone a Kasai hepatoportoenterostomy did not meet its primary endpoint of improved native liver survival. Topline safety data remained consistent with odevixibat's well-established pro its approved indications, with no new signals identified. External innovation Ipsen recently announced its agreement to acquire Kartos Therapeutics, a clinical-stage biopharmaceutical company, centered on navtemadlin, a Phase III oral MDM2 inhibitor for myelofibrosis designed to restore p53 tumor-suppressor activity in patients with a suboptimal response to ruxolitinib. Top-line data from the registrational POIESIS trial are expected in 2027. Under the terms of the agreement, Kartos shareholders will receive $450m upfront and may be eligible for up to $1.3bn in milestone payments, with closing anticipated by the end of Q3 2026, subject to customary conditions. Ipsen acquired Memo Therapeutics AG in July, a clinical-stage biotechnology company focused on potravitug, a Phase II antibody targeting BK polyomavirus (BKPyV), a frequent cause of nephropathy, graft loss and transplant failure in kidney transplant recipients. Potravitug received FDA Fast Track designation in 2023 and EU Orphan Drug designation in 2025. Under the terms of the agreement, Memo Therapeutics AG shareholders received €200m upfront, with the potential for total consideration exceeding €700m through development, regulatory and sales milestones. Consolidated financial statements The Board of Directors approved the condensed consolidated financial statements on 29 July 2026. The Company’s auditors performed a limited review of the H1 2026 condensed consolidated financial statements. The interim financial report, with regards to the regulated information, will be available on ipsen.com in due course, under the Reports and Accounts tab in the Investor Relations section. Conference call A conference call and webcast for investors and analysts will begin today at 2pm CEST. Participants can access the webcast here . Analysts can join the call and ask questions by registering here . Calendar Ipsen intends to publish its year-to-date and third-quarter sales update on 22 October 2026. Notes All financial figures are in € millions (€m). The performance shown in this announcement covers the six-month period to 30 June 2026 (H1 2026) and the three-month period to 30 June 2026 (Q2 2026), compared to the six-month period to 30 June 2025 (H1 2025) and the three-month period to 30 June 2025 (Q2 2025), respectively, unless stated otherwise. Commentary is based on the performance in H1 2026, unless stated otherwise. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com . Ipsen Contacts Investors Henry Wheeler henry.wheeler@ipsen.com +33 7 64 47 11 49 Khalid Deojee khalid.deojee@ipsen.com +33 6 66 01 95 26 Media Sally Bain sally.bain@ipsen.com +1 857 320 05 17 Anne Liontas anne.liontas.ext@ipsen.com +33 7 67 34 72 96 Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com . 1 At constant exchange rates (CER), which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 2 Excluding any impact from potential late-stage (Phase III clinical development or later) external-innovation transactions. 3 Subject to satisfaction of customary deal closing conditions 4 Excluding any impact from potential late-stage (Phase III clinical development or later) external-innovation transactions. Attachment Ipsen PR_HY 2026_30072026

Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is struggling to develop the trio. In May, the company grounded two investigational candidates. And now Ipsen has reported the failure of Bylvay in a phase 3 study that was designed to expand its patient population. The placebo-controlled Bold trial did not meet its primary endpoint, as Bylvay failed to extend the lives of biliary atresia (BA) patients who have undergone Kasai hepatoportoenterostomy (HPE) surgery. The procedure is performed on infants who have blocked bile ducts. It restores bile flow by connecting part of the small intestine directly to the liver. Ipsen did not elaborate further on Bylvay's performance in the prospective indication, though it stressed that present "topline data is in line with the well-established safety profile of odevixibat in approved indications." HPE can delay disease progression but does not always cure biliary atresia, which causes inflammation, fibrosis, cirrhosis and eventually liver failure. The only other option for these patients is a liver transplant, as there are no approved medicines for BA. The condition is the No. 1 cause of liver transplants in children under the age of 2, according to lead investigator Saul Karpen, M.D., Ph.D., the chief scientific officer of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University. “As the first global Phase 3 trial in biliary atresia, Bold has generated the most comprehensive dataset ever assembled in this disease,” Karpen added in a release. “Although the study did not meet its primary endpoint, the commitment of participating children and families has produced valuable insights that will deepen our understanding of biliary atresia and provide a crucial basis for future research and patient care.” Bylvay, a once-daily oral, is an ileal bile acid transport (IBAT) inhibitor that diverts bile acid to the feces, reducing its reabsorption in the intestine. It was approved in 2021 as a treatment for progressive familial intrahepatic cholestasis (PFIC) and two years later to relieve cholestatic pruritus (itching) associated with another liver disorder, Alagille syndrome. Last year, Ipsen posted (PDF) sales of Bylvay at 180 million euros ($203 million), which were up 36% over 2024. In its current indications, Ipsen competes with Mirum Pharmaceuticals’ IBAT Livmarli, which raked in sales of $360 million in 2025, up 69% year over year. In May, Mirum posted a phase 2 win in primary sclerosing cholangitis (PSC) for an investigational IBAT inhibitor. A week later, in the same indication, Ipsen shut down an open-label phase 2 trial of IBAT candidate ritivixibat because of recruitment issues and said it was discontinuing development of the Albireo asset. Around the same time, the company also removed another former Albireo liver disease candidate, A2342, from its list of pipeline drugs. Elsewhere, Ipsen has had a busy summer of business development. Four weeks ago, the company inked a $1.7 billion buyout of Kartos Therapeutics to gain a late-stage blood cancer candidate. A few days later, Ipsen scooped up Memo Therapeutics and its phase 2 BK polyomavirus candidate potravitug in a $700 million deal.